Cargando…
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
The major public health concern worldwide is coronary heart disease, with dyslipidemia as a major risk factor. Statin drugs are recommended by several guidelines for both primary and secondary prevention. Rosuvastatin has been widely accepted because of its efficacy, potency, and superior safety pro...
Autor principal: | Kones, Richard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023269/ https://www.ncbi.nlm.nih.gov/pubmed/21267417 http://dx.doi.org/10.2147/DDDT.S10812 |
Ejemplares similares
-
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
por: Narla, Venkata, et al.
Publicado: (2009) -
To JUPITER and beyond: Statins, inflammation, and primary prevention
por: Rao, Ajay D, et al.
Publicado: (2010) -
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
por: Kones, Richard
Publicado: (2011) -
Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial
por: Akinkuolie, Akintunde O., et al.
Publicado: (2016) -
The JUPITER study: statins for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases?
por: Ward, Michael M
Publicado: (2009)